10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 291.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,319,487 shares of the company's stock after buying an additional 982,203 shares during the quarter. Two Sigma Investments LP owned approximately 1.09% of 10x Genomics worth $18,948,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Teza Capital Management LLC purchased a new position in 10x Genomics during the fourth quarter valued at approximately $231,000. Sherbrooke Park Advisers LLC increased its holdings in 10x Genomics by 10.5% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 33,311 shares of the company's stock valued at $478,000 after buying an additional 3,162 shares during the period. Man Group plc grew its holdings in 10x Genomics by 77.6% in the fourth quarter. Man Group plc now owns 126,666 shares of the company's stock worth $1,819,000 after purchasing an additional 55,346 shares during the last quarter. Numerai GP LLC grew its holdings in 10x Genomics by 66.8% in the fourth quarter. Numerai GP LLC now owns 157,792 shares of the company's stock worth $2,266,000 after purchasing an additional 63,176 shares during the last quarter. Finally, Meridiem Capital Partners LP purchased a new position in 10x Genomics in the fourth quarter worth $4,924,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

10x Genomics Trading Up 0.2%

Shares of 10x Genomics stock traded up $0.01 during trading hours on Wednesday, reaching $8.60. The stock had a trading volume of 532,444 shares, compared to its average volume of 2,383,759. The stock's 50 day moving average is $8.52 and its 200 day moving average is $11.95. The firm has a market capitalization of $1.06 billion, a PE ratio of -5.62 and a beta of 1.94. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The firm had revenue of $154.88 million during the quarter, compared to the consensus estimate of $131.91 million. During the same quarter in the prior year, the firm earned ($0.50) EPS. The company's revenue for the quarter was down 2.3% on a year-over-year basis. As a group, sell-side analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Insider Activity at 10x Genomics

In other news, CFO Adam Taich sold 4,044 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total value of $33,565.20. Following the completion of the sale, the chief financial officer now owns 331,588 shares of the company's stock, valued at $2,752,180.40. This represents a 1.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 7,485 shares of the company's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total transaction of $62,125.50. Following the completion of the transaction, the insider now owns 448,374 shares in the company, valued at approximately $3,721,504.20. This represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,872 shares of company stock valued at $173,238. Corporate insiders own 9.39% of the company's stock.

Wall Street Analysts Forecast Growth

TXG has been the topic of several analyst reports. The Goldman Sachs Group cut their price target on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a report on Monday, May 12th. UBS Group cut their price target on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Barclays cut their price target on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Stifel Nicolaus cut their price target on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Finally, Leerink Partnrs lowered shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, 10x Genomics currently has a consensus rating of "Hold" and an average target price of $15.81.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.